Nouvelle déclaration d'incident
No de la demande: 2022-1696
Numéro de référence du titulaire d'homologation: 2022-US-000795
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: UNITED STATES
État: ALABAMA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2596-83
Nom du produit: Hartz UltraGuard Flea and Tick Collar for Cats and Kittens - Purple
Autre (préciser)
CollarOui
Inconnu
Site: Animal / Usage sur un animal domestique
Propriétaire de l'animal
Cat / Chat
Domestic Longhair
1
Femme
6
7
lbs
Cutanée
>1 wk <=1 mo / > 1 sem < = 1 mois
>3 days <=1 wk / >3 jours <=1 sem
Système
Persisted until death
Oui
Inconnu
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On approximately 01-Jan-2022, a 6 year old, approximately 7 pound, neutered, female, Domestic Longhair cat, in unknown condition, with no known concomitant medical condition, had 1 collar of Hartz UltraGuard Flea and Tick Collar for Cats and Kittens - Purple (Tetrachlorvinphos) applied via the topical route by the animal owner. On 08-Jan-2022 the cat developed ataxia, trembling, seizures, and was unable to walk. The cat was evaluated by a veterinarian and was administered Valium (diazepam) and other unspecified treatments. On 09-Jan-2022 the cat died. It was not specified if the cat died while still in veterinary care or at home. No further information was received.
Mort
Assessment: This product contains tetrachlorvinphos, an organophosphate insecticide, that is considered to have a good margin of safety in cats. The active ingredient is poorly absorbed across intact skin. If product residue were ingested only mild GI upset would be expected. Severe neurological signs beginning one week after application and progressing to death are not expected. Other causes including misuse of a pyrethroid containing topical product for dogs, underlying disease, severe anemia secondary to flea infestation, and other exposures should also be considered. Direct consultation with the treating veterinarian did not occur in this case so examination findings, diagnostics, and other treatments performed remain unknown. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.